Allogene Therapeutics, Inc. Cash Flow Statement
ALLO|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
Allogene Therapeutics, Inc. used $149M in operating cash flow and negative free cash flow of $150M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | -$190.9M | -$327.3M | -$182.1M | -$158.9M | -$184.6M |
| Depreciation & Amortization | $12.4M | $14.2M | $10.5M | $14.3M | $4.6M |
| Operating Cash Flow | -$149.2M | -$237.7M | -$184.8M | -$110.8M | -$137.3M |
| Capital Expenditures | $386.0K | $1.5M | $21.4M | $5.2M | $50.8M |
| Free Cash Flow | -$149.6M | -$239.2M | -$206.3M | -$116.0M | -$188.1M |
| FCF Margin | - | -251841.0% | -180.8% | -112581.5% | - |